Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pfizer Raises Forecast on Robust Drug Sales, Offsets COVID-19 Revenue Decline

Pfizer (PFE) raised its annual profit forecast, driven by robust sales in its cancer and heart disease drug segments, particularly benefiting from its recent acquisition of Seagen. The pharmaceutical giant...

SGEN : 228.74 (-0.07%)
BNTX : 115.62 (-7.29%)
JPM : 207.53 (-0.82%)
Pfizer: From pandemic hero to investor jitters

Pfizer's transitions from pandemic success to market concerns: analyzing revenue stagnation, investor reactions, and the company's strategic roadmap for growth.

PFE : 29.75 (-0.27%)
SGEN : 228.74 (-0.07%)
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.

MRK : 118.64 (+0.30%)
PFE : 29.75 (-0.27%)
SGEN : 228.74 (-0.07%)
This High-Yield Dividend Stock Is a Proven Wealth Creator

This heavily sold-off pharma stock is a bargain.

SGEN : 228.74 (-0.07%)
PFE : 29.75 (-0.27%)
Seattle Genetics: Q3 Earnings Snapshot

Seattle Genetics: Q3 Earnings Snapshot

SGEN : 228.74 (-0.07%)
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?

The venerable pharmaceutical companies' shares have slumped this year.

BMY : 49.74 (+0.51%)
SGEN : 228.74 (-0.07%)
REGN : 1,138.81 (-0.69%)
BNTX : 115.62 (-7.29%)
PFE : 29.75 (-0.27%)
RHHBY : 39.6100 (+0.71%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

/PRNewswire/ -- USA News Group - According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic...

ONC.TO : 1.28 (-1.54%)
BNTX : 115.62 (-7.29%)
ONCY : 0.9300 (-2.99%)
SGEN : 228.74 (-0.07%)
MYGN : 28.47 (-0.45%)
ILMN : 130.97 (+0.58%)
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
SGEN : 228.74 (-0.07%)
MYGN : 28.47 (-0.45%)
ILMN : 130.97 (+0.58%)
BNTX : 115.62 (-7.29%)
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
GNLX : 2.45 (-3.54%)
CRNX : 52.77 (-0.42%)
PFE : 29.75 (-0.27%)
SGEN : 228.74 (-0.07%)
Navigating the Surge in Pancreatic Cancer: The Innovative Strategies Offering New Hope

USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
GNLX : 2.45 (-3.54%)
CRNX : 52.77 (-0.42%)
PFE : 29.75 (-0.27%)
SGEN : 228.74 (-0.07%)

Barchart Exclusives

Stocks Soar Before the Open as Fed’s Big Rate Cut Boosts Sentiment, U.S. Economic Data and FedEx Earnings on Tap
September S&P 500 E-Mini futures (ESU24) are up +1.48%, and September Nasdaq 100 E-Mini futures (NQU24) are up +2.03% this morning on expectations the Federal Reserve’s half-percentage-point rate cut will steer the U.S. economy toward a “soft landing,” while investors awaited a new round of U.S. economic data and an earnings report from delivery services giant FedEx. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar